: Nai-Kong CHEUNG Atty. Dkt. # Applicant : 639-C-PCT-US : 1623

USSN : 10/565,484 Art Unit

: 01/17/2006 Date of Office Action : 12/17/2008 Filed Date of Response : 03/10/2008 Examiner : Eric Olson

Page : 3

## AMENDMENT TO THE CLAIMS

This listing of claims will replace all prior listings or versions of claims in this application.

## 1-13. (Canceled)

- 14. (Currently Amended) A composition comprising:
  - a composition comprising an antibody that binds to a at least one pharmaceutically cancer cell, and acceptable carrier, wherein the cancer is selected from the group consisting of neuroblastoma, melanoma, non-Hodgkin's lymphoma, breast cancer, Epstein-Barr related lymphoma, Hodgkin's lymphoma, and epidermoid carcinoma; and
  - an orally administered composition comprising at least one pharmaceutically acceptable carrier and a soluble  $\beta$ glucan in an amount effective to enhance the antitumor effect of said antibody, wherein the  $\beta$ -glucan comprises a  $\beta-1.3$  backbone and at least one  $\beta-1.3$  side chain of two or more glucose units linked to the backbone by a  $\beta-1,6$ glycosidic bonds.
- 15. (Previously presented) The composition of claim 14, wherein the  $\beta$ -glucan is isolated from yeast.
- 16. (Previously presented) The composition of claim 14, wherein the β-glucan is isolated from Saccharomyces Cerevisiae.

Applicant : Nai-Kong CHEUNG Atty. Dkt. # : 639-C-PCT-US

USSN : 10/565,484 Art Unit : 1623

Filed : 01/17/2006 Date of Office Action : 12/17/2008 Examiner : Eric Olson Date of Response : 03/10/2008

Page: 4

17. (Previously presented) The composition of claim 14, wherein the  $\beta$ -glucan has a molecular weight from about 10 kDa to about 350 kDa and is capable of inducing cytokines.

## 18. (Canceled)

- 19. (Previously presented) The composition of claim 14, wherein the antibody is a monoclonal antibody or a complement-activating antibody.
- 20. (Previously presented) The composition of claim 14, wherein the antibody binds to a cancer cell expressing an antigen selected from the group consisting of CD20, HER2, EGFR, GD2, and GD3.
- 21. (Previously presented) The composition of claim 14, wherein the antibody is further capable of activating an antibody dependent cell-mediated cytotoxicity response.
  - 22. (Currently Amended) A composition comprising:
    - (a) a composition comprising an antibody that binds to a cancer cell, and at least one pharmaceutically acceptable carrier, wherein the antibody binds to a cancer cell expressing an antigen selected from the group consisting of CD20, HER2, EGFR, GD2, and GD3; and
    - (b) an orally administered composition comprising at least one pharmaceutically acceptable carrier and a <u>soluble</u>  $\beta$ -glucan in an amount effective to enhance the antitumor effect of said antibody, wherein the  $\beta$ -glucan comprises a

Applicant : Nai-Kong CHEUNG Atty. Dkt. # : 639-C-PCT-US: USSN : 10/565,484 Art Unit : 1623

Filed : 01/17/2006 Date of Office Action : 12/17/2008 Examiner : Eric Olson Date of Response : 03/10/2008

Page : 5

 $\beta$ -1,3 backbone and at least one  $\beta$ -1,3 side chain of two or more glucose units linked to the backbone by a  $\beta$ -1,6 glycosidic bond.

- 23. (Previously presented) The composition of claim 22, wherein the  $\beta$ -qlucan is isolated from yeast.
- 24. (Previously presented) The composition of claim 22, wherein the  $\beta$ -glucan is isolated from Saccharomyces Cerevisiae.
- 25. (Previously presented) The composition of claim 22, wherein the  $\beta$ -glucan has a molecular weight from about 10 kDa to about 350 kDa and is capable of inducing cytokines.
- 26. (Canceled)
- 27. (Previously presented) The composition of claim 22, wherein the antibody is a monoclonal antibody or a complement-activating antibody.
- 28. (Previously presented) The composition of claim 22, wherein the cancer cell is selected from the group consisting of neuroblastoma, melanoma, non-Hodgkin's lymphoma, breast cancer, Epstein-Barr related lymphoma, Hodgkin's lymphoma, and epidermoid carcinoma.
- 29. (Previously presented) The composition of claim 22, wherein the antibody is further capable of activating an antibody dependent cell-mediated cytotoxicity response.